| 2016-11-21 07:32:56|
LGND, RTRX 07:32 11/21 11/21/16
Ligand says Retrophin reports added 'positive' data from study of sparsentan
Ligand Pharmaceuticals (LGND) reported that its partner Retrophin (RTRX) announced additional results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis, a rare kidney disorder without an FDA-approved pharmacologic treatment that often leads to end-stage renal disease. These new findings are being presented today in the late-breaking High-Impact Clinical Trials oral session at the American Society of Nephrology Kidney Week 2016 in Chicago. As announced in September, top-line data from DUET showed the sparsentan treatment group achieved statistical significance in the study's primary efficacy endpoint, reduction of proteinuria. These results showed a greater than two-fold reduction of proteinuria compared to irbesartan, after an eight-week, double-blind treatment period. An analysis of the secondary endpoint presented today showed that a significantly greater proportion of patients receiving sparsentan achieved modified partial remission of proteinuria, compared to irbesartan-treated patients. "These new results add to the growing body of evidence from the DUET study, reinforcing our confidence that sparsentan may represent a significant advancement in the treatment of FSGS," said Stephen Aselage, CEO of Retrophin.